Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Ophthalmology

Managing Your Vision: Monitoring and Complication Care

At a Glance

Best Vitelliform Macular Dystrophy (BVMD) is primarily managed through routine monitoring to detect serious complications like choroidal neovascularization (CNV). If sudden wavy vision or new blind spots occur, immediate anti-VEGF injections can effectively stop vessel growth and preserve vision.

Because Best Vitelliform Macular Dystrophy (BVMD) usually progresses very slowly, the primary goal of medical management is “watchful waiting” and the early detection of complications [1][2]. While there is currently no cure for the underlying genetic mutation, the most significant risk to your vision—abnormal blood vessel growth—is highly treatable if caught early [3][4].

The Main Complication: CNV

The most serious complication in BVMD is Choroidal Neovascularization (CNV). This occurs when fragile, abnormal blood vessels grow underneath the retina [5]. These vessels can leak fluid or blood, which can cause a sudden and significant drop in central vision if left untreated [4][3].

Symptoms of CNV include:

  • Metamorphopsia: Straight lines (like door frames or lines on a page) appearing wavy, bent, or distorted [6].
  • New Blind Spots: A sudden “smudge” or dark spot in the center of your vision.
  • Rapid Decrease in Vision: Changes happening over a few days or weeks (rather than years) that do not improve with better lighting.

Treatment: Anti-VEGF Therapy

If CNV is detected, the standard of care is intravitreal anti-VEGF injections (such as bevacizumab, ranibizumab, or aflibercept) [3][4].

  • What is an intravitreal injection? It is an injection of medication directly into the fluid-filled center of the eye. While this sounds terrifying, doctors use strong numbing drops or gels beforehand, making the procedure feel like slight pressure rather than a sharp pain.
  • Effectiveness: Anti-VEGF therapy is highly effective at stopping abnormal vessel growth, stabilizing vision, and reducing fluid in BVMD patients [4][7].

Your Monitoring Action Plan

Routine monitoring is the best way to protect your sight. Your doctor will likely use Optical Coherence Tomography Angiography (OCTA), a non-invasive scan that can see these tiny blood vessels without the need for dye injections [8][9].

Tool Frequency Purpose
Amsler Grid Daily To catch sudden waviness or distortions at home. Critical Instruction: You must test one eye at a time while wearing normal reading glasses. If you test with both eyes open, your brain will compensate and mask any distortions.
OCT Scan Every 6–12 months* To monitor waste buildup and check for fluid [10].
OCTA Scan As needed To detect or monitor abnormal blood vessel growth [8].
Dilated Exam Annually To check the overall health of the retina and RPE [10].
*Frequency may increase if you are in a more advanced stage or have had CNV before [2].

When to Call the Doctor Immediately

You should contact your retinal specialist the same day if you notice:

  1. A sudden “wave” in a straight line on your Amsler grid.
  2. A new dark spot or “void” in your central vision.
  3. A rapid decrease in your ability to read that happens over days/weeks, not years.

Early intervention with anti-VEGF therapy is the key to preventing permanent scarring and preserving the vision you have for as long as possible [3][5]. While today’s treatments focus on complications, researchers are actively looking for a cure. Read more in Future Research & Gene Therapy.

Common questions in this guide

What is the most serious complication of Best Vitelliform Macular Dystrophy?
The most serious complication is choroidal neovascularization (CNV). This occurs when fragile, abnormal blood vessels grow underneath the retina and leak fluid or blood, which can cause a sudden and significant drop in your central vision.
How do you treat abnormal blood vessel growth in BVMD?
If abnormal blood vessels (CNV) are detected, the standard treatment is intravitreal anti-VEGF injections, such as bevacizumab, ranibizumab, or aflibercept. These medications are highly effective at stopping abnormal vessel growth and stabilizing your vision.
How should I use an Amsler grid at home?
You should use an Amsler grid daily to check for sudden waviness or distortions. It is critical to test one eye at a time while wearing your normal reading glasses. If you test with both eyes open, your brain may compensate and hide any visual distortions.
What vision changes mean I need to call my eye doctor immediately?
Contact your retinal specialist the same day if you notice a sudden 'wave' in straight lines, a new dark spot in your central vision, or a rapid decrease in your ability to read that happens over a few days or weeks.
How often do I need OCT scans to monitor my BVMD?
Your doctor will likely use Optical Coherence Tomography (OCT) scans every 6 to 12 months to monitor waste buildup and check for fluid. You may also need OCT Angiography (OCTA) scans as needed to detect abnormal blood vessel growth, and an annual dilated exam.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I showing any 'red flag' imaging signs, like focal choroidal excavations or nodular pillars, that might increase my risk for CNV?
  2. 2.Based on my current stage, how often should I be coming in for OCT and OCTA scans?
  3. 3.Can you help me set a baseline for my Amsler grid results so I know exactly what counts as a 'new' change?
  4. 4.If I develop CNV, what is your standard approach for anti-VEGF injections?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    Best Vitelliform Macular Dystrophy.

    Tsang SH, Sharma T

    Advances in experimental medicine and biology 2018; (1085()):79-90 doi:10.1007/978-3-319-95046-4_16.

    PMID: 30578489
  2. 2

    Best Vitelliform Macular Dystrophy Natural History Study Report 2: Fundus Autofluorescence and OCT.

    Laich Y, Georgiou M, Fujinami K, et al.

    Ophthalmology. Retina 2025; (9(9)):899-907 doi:10.1016/j.oret.2025.03.004.

    PMID: 40086732
  3. 3

    Intravitreal bevacizumab treatment for exudative choroidal neovascularisation in best vitelliform macular dystrophy.

    Jarc-Vidmar M, Sega R, Jaki-Mekjavic P

    European journal of ophthalmology 2021; 11206721211057684 doi:10.1177/11206721211057684.

    PMID: 34779297
  4. 4

    Choroidal Neovascularization Associated with Best Vitelliform Macular Dystrophy.

    Adiyeke SK, Ture G

    Beyoglu eye journal 2022; (7(2)):103-108 doi:10.14744/bej.2022.54376.

    PMID: 35692272
  5. 5

    Choroidal Neovascularization Is Common in Best Vitelliform Macular Dystrophy and Plays a Role in Vitelliform Lesion Evolution.

    Han IC, Coussa RG, Mansoor M, et al.

    Ophthalmology. Retina 2023; (7(5)):441-449 doi:10.1016/j.oret.2022.11.014.

    PMID: 36528270
  6. 6

    Fixation Location and Stability in Best Vitelliform Macular Dystrophy.

    Bianco L, Arrigo A, Marchese A, et al.

    Ophthalmology science 2023; (3(4)):100329 doi:10.1016/j.xops.2023.100329.

    PMID: 37304042
  7. 7

    Vitreoretinal Procedures in Patients with Inherited Retinal Disease.

    Fenner BJ, Jamshidi F, Bhuyan R, et al.

    Ophthalmology. Retina 2024; (8(3)):307-309 doi:10.1016/j.oret.2023.10.020.

    PMID: 37918655
  8. 8

    OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FOR THE DETECTION OF SECONDARY CHOROIDAL NEOVASCULARIZATION IN VITELLIFORM MACULAR DYSTROPHY.

    Stattin M, Ahmed D, Glittenberg C, et al.

    Retinal cases & brief reports 2020; (14(1)):49-52 doi:10.1097/ICB.0000000000000626.

    PMID: 28817420
  9. 9

    A Case of Best Disease Accompanied by Pachychoroid Neovasculopathy

    Batıoğlu F, Yanık Ö, Demirel S, et al.

    Turkish journal of ophthalmology 2019; (49(4)):226-229 doi:10.4274/tjo.galenos.2019.38073.

    PMID: 31486612
  10. 10

    Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights.

    Bianco L, Arrigo A, Antropoli A, et al.

    European journal of ophthalmology 2024; (34(1)):39-51 doi:10.1177/11206721231166434.

    PMID: 36972471

This page is for informational purposes only and does not replace professional medical advice. Always contact your ophthalmologist or retina specialist immediately if you experience sudden vision changes.

Get notified when new evidence is published on Best vitelliform macular dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.